Nirogacestat
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Androgenic hidradenitis suppurativa onset linked to gamma secretase inhibitor.
Journal: JAAD case reports
Published: January 09, 2026
Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025
Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor.
Journal: Frontiers in oncology
Published: September 27, 2025
Disproportionality Analysis of Dermatologic Adverse Events Associated with Nirogacestat: Insights from the FDA Adverse Event Reporting System (FAERS).
Journal: Journal of the American Academy of Dermatology
Published: September 05, 2025
Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.
Journal: Future oncology (London, England)
Published: September 01, 2025
Rapid biocompatible solid phase microextraction: Nirogacestat protein binding in post dose human serum samples.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: August 29, 2025
New onset hidradenitis suppurativa and eruptive milia associated with gamma secretase inhibitor therapy in a patient with desmoid tumor: A case report.
Journal: JAAD case reports
Published: August 11, 2025
Clinical Challenges and Evolving Treatments in Desmoid Fibromatosis: A Single Institution Experience.
Journal: Cancer investigation
Published: April 21, 2025
UPLC-LCMS-Based Method Development, Validation, Forced Degradation, and Impurity Profiling of Nirogacestat Drug Substance.
Journal: Current topics in medicinal chemistry
Published: April 16, 2025
Last Updated: 02/24/2026